APA (7th ed.) Citation

Chouaid, C., Thomas, M., Debieuvre, D., Durand-Zaleski, I., Zacharias, S., Bosquet, L., . . . Griesinger, F. (2022). Effectiveness of Nivolumab in second-line and later in patients with advanced non-small cell lung cancer in real-life practice in France and Germany: Analysis of the ESME-AMLC and CRISP cohorts. Cancers, 14(24), . https://doi.org/10.3390/cancers14246148

Chicago Style (17th ed.) Citation

Chouaid, Christos, et al. "Effectiveness of Nivolumab in Second-line and Later in Patients with Advanced Non-small Cell Lung Cancer in Real-life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts." Cancers 14, no. 24 (2022). https://doi.org/10.3390/cancers14246148.

MLA (9th ed.) Citation

Chouaid, Christos, et al. "Effectiveness of Nivolumab in Second-line and Later in Patients with Advanced Non-small Cell Lung Cancer in Real-life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts." Cancers, vol. 14, no. 24, 2022, https://doi.org/10.3390/cancers14246148.